Veriphi Shareholder Update: 16 June 2017

Auckland Hospital Preliminary Trials 100% Successful.  As discussed in our 10 June Update, yesterday we conducted our first blind trials with our new analyser, on 5 anaesthetic drugs and solutions, at Auckland City Hospital Department of Anaesthesia. The purpose of the trials was to assess the impact of transporting our new analyser to a different location and conducting tests in …

Veriphi Shareholder Update: 14 June 2017

Auckland Hospital Research Governance Committee Gives Approval. Further to our Shareholder Update on 10 June, I am writing to let you know that the Auckland Hospital Research Governance Committee has given approval for our hospital trial, on 5 oncology drugs, to proceed.  Testing in preparation for the formal trial starts at the hospital tomorrow. Auckland Hospital Progress.   We anticipate the …

Veriphi Shareholder Update: 27 May 2017

Introduction. As good technical progress continues, the main focus for the business is capital raising and expediting first revenues. There is a dearth of Series A funders for businesses like Veriphi, however we are making headway. In addition, our expenses and cash burn are below forecast, therefore extending our cash runway. Commercial Progress Commercial Approaches – In parallel to our …

Veriphi Shareholder Update: 24 April 2017

Cash Flow and Investment: R & D Tax Loss Credit– In 10 days we will receive a $48k refund from the IRD, as a credit for our R&D tax losses. Grant Claim – We have made our first claim for our Callaghan Innovation Growth Grant, for $32k. Pro rata Investment – Indicative investment from shareholders to exercise their pro rata …